ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1064
CHEMBL1064
Compound Name SIMVASTATIN
ChEMBL Synonyms ZOCOR | LACERSA | SYNVINOLIN | Simvastatin hydroxy acid | ZOCOR HEART-PRO | FLOLIPID | SIMVASTATIN | RANZOLONT | SIMVADOR | MK-733
Max Phase 4 (Approved)
Trade Names LACERSA | ZOCOR | RANZOLONT | SIMVASTATIN | SIMVADOR | FLOLIPID | ZOCOR HEART-PRO
Molecular Formula C25H38O5

Additional synonyms for CHEMBL1064 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H] ...
Download SMILES
Standard InChI InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7- ...
Download InChI
Standard InChI Key RYMZZMVNJRMUDD-HGQWONQESA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Metabolism Pathways
  • Curated Drug Pharmacokinetic Data
  • DrugMatrix
  • FDA Approval Packages
  • HeCaToS Compounds
  • Open TG-GATEs
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1064

Molecule Features

CHEMBL1064 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:Y Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
HMG-CoA reductase inhibitor HMG-CoA reductase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Acute Coronary SyndromeD054058EFO:0005672acute coronary syndrome3ClinicalTrials
AtherosclerosisD050197EFO:0003914atherosclerosis0ClinicalTrials
HypercholesterolemiaD006937HP:0003124hypercholesterolemia4ClinicalTrials
DailyMed
HypertriglyceridemiaD015228EFO:0004211Hypertriglyceridemia3ClinicalTrials
PneumoniaD011014EFO:0003106pneumonia3ClinicalTrials
Stomach NeoplasmsD013274EFO:0000178gastric carcinoma3ClinicalTrials
Bipolar DisorderD001714EFO:0000289bipolar disorder2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma3ClinicalTrials
Diabetic RetinopathyD003930EFO:0003770diabetic retinopathy3ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy1ClinicalTrials
Graves OphthalmopathyD049970EFO:1001466Graves ophthalmopathy3ClinicalTrials
Migraine DisordersD008881EFO:0003821migraine disorder2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
PainD010146EFO:0003843pain1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
Vascular DiseasesD014652EFO:0004264vascular disease1ClinicalTrials
VitiligoD014820EFO:0004208Vitiligo2ClinicalTrials
Waldenstrom MacroglobulinemiaD008258EFO:0002616macroglobulinemia2ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation2ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus3ClinicalTrials
Hyperlipidemia, Familial CombinedD006950Orphanet:79211Combined hyperlipidemia3ClinicalTrials
HypertensionD006973EFO:0000537hypertension3ClinicalTrials
Liver CirrhosisD008103EFO:0001422cirrhosis of liver2ClinicalTrials
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus1ClinicalTrials
Peripheral Arterial DiseaseD058729EFO:0004265peripheral arterial disease2ClinicalTrials
Shock, SepticD012772EFO:0006834septic shock2ClinicalTrials
Small Cell Lung CarcinomaD055752EFO:0000702small cell lung carcinoma2ClinicalTrials
Cystic FibrosisD003550Orphanet:586Cystic fibrosis1ClinicalTrials
Myocardial IschemiaD017202EFO:1001375Myocardial Ischemia3ClinicalTrials
Polycystic Ovary SyndromeD011085EFO:0000660polycystic ovary syndrome3ClinicalTrials
Urinary Bladder NeoplasmsD001749EFO:0000292bladder carcinoma2ClinicalTrials
Alopecia AreataD000506EFO:0004192alopecia areata1ClinicalTrials
ChoroideremiaD015794Orphanet:180Choroideremia1ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus2ClinicalTrials
DyslipidemiasD050171HP:0003119Abnormality of lipid metabolism4DailyMed
Hyperlipoproteinemia Type IID006938EFO:0004911familial hypercholesterolemia4ClinicalTrials
DailyMed
Intestinal NeoplasmsD007414EFO:0007330intestinal cancer3ClinicalTrials
LeiomyomaD007889EFO:0000731uterine fibroid2ClinicalTrials
MucositisD052016EFO:1001898mucositis2ClinicalTrials
Myocardial InfarctionD009203EFO:0000612myocardial infarction3ClinicalTrials
Noonan SyndromeD009634Orphanet:648Noonan syndrome3ClinicalTrials
Pulmonary Disease, Chronic ObstructiveD029424EFO:0000341chronic obstructive pulmonary disease3ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer2ClinicalTrials
Sleep Initiation and Maintenance DisordersD007319EFO:0004698insomnia1ClinicalTrials
Smoking CessationD016540EFO:0004319smoking cessation2ClinicalTrials
Anemia, Sickle CellD000755Orphanet:232Sickle cell anemia1ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection1ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia1ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis3ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma2ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis1ClinicalTrials
AsthmaD001249EFO:0000270asthma3ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease3ClinicalTrials
Heart FailureD006333EFO:0003144heart failure0ClinicalTrials
Hemangioma, Cavernous, Central Nervous SystemD020786EFO:1001343Hemangioma, Cavernous, Central Nervous System0ClinicalTrials
Intermittent ClaudicationD007383EFO:0003876intermittent vascular claudication2ClinicalTrials
Lipid Metabolism DisordersD052439Orphanet:309005Disorder of lipid metabolism3ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer0ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease3ClinicalTrials
SepsisD018805HP:0100806sepsis2ClinicalTrials
SinusitisD012852EFO:0007486sinusitis2ClinicalTrials
Subarachnoid HemorrhageD013345EFO:0000713subarachnoid hemorrhage3ClinicalTrials
UveitisD014605EFO:1001231uveitis2ClinicalTrials
Acute Kidney InjuryD058186HP:0001919Acute kidney injury1ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease3ClinicalTrials
Aortic Valve StenosisD001024EFO:0000266aortic stenosis3ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Carotid Artery DiseasesD002340EFO:0003781carotid artery disease2ClinicalTrials
Cerebral HemorrhageD002543EFO:0005669intracerebral hemorrhage2ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
Hepatitis B, ChronicD019694EFO:0004197hepatitis B infection1ClinicalTrials
HyperlipidemiasD006949EFO:0003774hyperlipidemia4ClinicalTrials
DailyMed
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension2ClinicalTrials
InflammationD007249MP:0001845inflammation3ClinicalTrials
Multiple Sclerosis, Chronic ProgressiveD020528EFO:0003840chronic progressive multiple sclerosis3ClinicalTrials
PeriodontitisD010518EFO:0000649periodontitis2ClinicalTrials
Prediabetic StateD011236EFO:1001121prediabetes syndrome2ClinicalTrials
Smith-Lemli-Opitz SyndromeD019082Orphanet:818Smith-Lemli-Opitz syndrome2ClinicalTrials
Stomach NeoplasmsD013274EFO:0003897stomach neoplasm3ClinicalTrials

Clinical Data

ClinicalTrials.gov SIMVASTATIN
The Cochrane Collaboration SIMVASTATIN

Metabolites for CHEMBL1064

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1064. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000
CHEMBL5956 Beta-lactamase SHV-1 Escherichia coli 0.999
CHEMBL276 Muscarinic acetylcholine receptor M1 Rattus norvegicus 0.881
CHEMBL317 Muscarinic acetylcholine receptor M4 Rattus norvegicus 0.802
CHEMBL4349 N-acylsphingosine-amidohydrolase Homo sapiens 0.615
CHEMBL2034805 N-acylethanolamine-hydrolyzing acid amidase Rattus norvegicus 0.486
CHEMBL211 Muscarinic acetylcholine receptor M2 Homo sapiens 0.453
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.450
CHEMBL3056 Androgen Receptor Mus musculus 0.436
CHEMBL3272 Cathepsin L2 Homo sapiens 0.296
CHEMBL4662 Proteasome Macropain subunit MB1 Homo sapiens 0.285
CHEMBL2672 Muscarinic acetylcholine receptor M1 Bos taurus 0.256
CHEMBL2878 Histone deacetylase 6 Mus musculus 0.211



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000
CHEMBL1697668 Solute carrier organic anion transporter family member 1B1 Homo sapiens 1.000
CHEMBL1743121 Solute carrier organic anion transporter family member 1B3 Homo sapiens 1.000
CHEMBL5956 Beta-lactamase SHV-1 Escherichia coli 1.000
CHEMBL276 Muscarinic acetylcholine receptor M1 Rattus norvegicus 0.964
CHEMBL317 Muscarinic acetylcholine receptor M4 Rattus norvegicus 0.892
CHEMBL3721 Cytochrome P450 2C8 Homo sapiens 0.688
CHEMBL4796 Beta-chymotrypsin Homo sapiens 0.491
CHEMBL2672 Muscarinic acetylcholine receptor M1 Bos taurus 0.377
CHEMBL2878 Histone deacetylase 6 Mus musculus 0.305
CHEMBL1828 DNA polymerase alpha subunit Homo sapiens 0.230
CHEMBL3482 Beta-galactosidase Bos taurus 0.226

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
418.6 418.2719 4.59 6 72.83 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 5 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.49 - 4.72 4.72 0 30 0.64

Structural Alerts

There are 1 structural alerts for CHEMBL1064. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C10 - LIPID MODIFYING AGENTS
C10A - LIPID MODIFYING AGENTS, PLAIN
C10AA - HMG CoA reductase inhibitors
C10AA01 - simvastatin

ChemSpider ChemSpider:RYMZZMVNJRMUDD-HGQWONQESA-N
DailyMed simvastatin
PubChem SID: 144204247 SID: 144210718 SID: 164339438 SID: 170464984 SID: 496592 SID: 50086525
Wikipedia Simvastatin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1064



ACToR 79902-63-9
Atlas simvastatin
BindingDB 50139181
Brenda 2311 39735
ChEBI 9150
DrugBank DB00641
DrugCentral 2445
eMolecules 36754543 11021557 2724261
EPA CompTox Dashboard DTXSID0023581
FDA SRS AGG2FN16EV
Guide to Pharmacology 2955
Human Metabolome Database HMDB0005007
IBM Patent System 7FCC9C14BC71D6D3F54342078D97EF09
LINCS LSM-2492
Mcule MCULE-8390617062
MolPort MolPort-002-507-345
NIH Clinical Collection SAM002589969
Nikkaji J152.218C
NMRShiftDB 20168321
PharmGKB PA451363
PubChem 54454
PubChem: Drugs of the Future 12013879
PubChem: Thomson Pharma 14831549 14929313
Selleck Simvastatin(Zocor)
SureChEMBL SCHEMBL2471
ZINC ZINC000003780893

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/RYMZZMVNJRMUDD-HGQWONQESA-N spacer
spacer